The latest published New report by Polaris Market Research The report “Mucormycosis Market Share, Size, Trends, Industry Analysis Report; By Diagnosis (Computed Tomography, MRI, Tissue Biopsy); By Treatment (Surgery, Antifungal Drugs, Amphotericin B Therapy, Others); By End-Use; By Region; Segment Forecast, 2021 – 2028” its covers an exhaustive list of market tables and figures, thus providing in-depth analytical data for segments across different regions.
Market Analysis:
The global mucormycosis market was valued at USD 422.7 million in 2020 and is expected to reach USD 616.1 million by 2028 to grow at a CAGR of 3.4% during the forecast period [2021 – 2028]. The emergence of the COVID-19 pandemic along with the increasing cases of blood cancers and diabetes will be the main factors for the growth of the global market during the forecast period. Organ and bone marrow transplantation along with increasing immune-competent patients due to the conditions like HIV will also boost the growth of the global market.
Get Sample Copy: https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-sample
COVID-19 has significantly impacted the globe with over 150 million cases detected worldwide. Brazil is the third-worst affected country with more than 15 million cases and India which is clocking more cases than any other country, in May 2021, and has detected more than 20 million cases from the beginning of the pandemic. Mucormycosis cases are increased in the COVID-19 patients who have undergone treatment.
Competitive Insight:
Biocon Limited, Abbott Laboratories, Cadila Pharmaceuticals Limited, F. Hoffman La Roche, Novartis AG, Merck Sharp and Dohme, Bristol Myers Squibb, Mylan Labs, Bayer AG, Sanofi, Lonza Group, Johnson & Johnson, Gilead Sciences and Pfizer Inc.
Market Insight:
In India, there is an enormous increase in fungal infection, and in few hospitals in urban areas, five to ten people are coming for mucormycosis treatment. Before the pandemic, mucormycosis was very rare and the emergence of COVID-19 is expected to give a major boost to the growth of the global market.
Every year nearly 1.8 million hematological cancers are diagnosed across the globe and bone marrow transplantation is a treatment procedure to treat these conditions. The improved technology has resulted in the increased organ transplantation in the market.
In the U.S. market alone, nearly, 37,000 organ transplant procedures were conducted, in 2018. Most of the patients who underwent transplant take immunosuppressive drugs which will put them at the risk of developing mucormycosis.
Get Exclusive Discount offer @ https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-discount-pricing
Mucormycosis is a deadly fungal disease caused by species such as Rhizopus, Mucor, Saksenaea, Apophysomyces, Lichtheimia, Cunninghamella, Rhizomucor, and others. The mortality rate of mucormycosis ranges from 17 to 66% in patients and the patients who overcome mucormycosis will suffer from blindness and organ dysfunction.
Table of Contents
- Introduction
- Report Description
- Objectives of the Study
- Market Scope
- Assumptions
- Stakeholders
- Report Description
- Executive Summary
- Market Highlights
- Research Methodology
- Overview
- Data Mining
- Data Mining
3.2.1 Primary Sources
3.2.2 Secondary Sources
- Overview
- Mucormycosis Market Insights
- Mucormycosis – Industry snapshot
- Mucormycosis Market Dynamics
- Drivers and Opportunities
- Surge in fungal infections
- Extensive use of immunosuppressants and steroids
- Restraints and Challenges
- Slow diagnosis rate
- Drivers and Opportunities
- Porter’s Five Forces Analysis
- Bargaining Power of Suppliers (Moderate)
- Threats of New Entrants: (Low)
- Bargaining Power of Buyers (Moderate)
- Threat of Substitute (Moderate)
- Rivalry among existing firms (High)
- PESTLE Analysis
- Mucormycosis Market Industry trends
- Mucormycosis Market Assessment by Diagnosis
- Key Findings
- Introduction
- Global Mucormycosis Market, By Diagnosis, 2016 – 2028 (USD Million)
- Computed Tomography (CT)
- Global Mucormycosis Market, by Computed Tomography (CT), By Region, 2016- 2028 (USD Million)
- Magnetic Resonance Imaging (MRI)
- Global Mucormycosis Market, by Magnetic Resonance Imaging (MRI), by Region, 2016- 2028 (USD Million)
- Tissue Biopsy
- Global Mucormycosis Market, by Tissue Biopsy, by Region, 2016- 2028 (USD Million)
- Others
- Global Mucormycosis Market, by Others, by Region, 2016- 2028 (USD Million)
Or
Find more research reports on Healthcare Industry by Polaris Market Research
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavour to deliver value-added business solutions to our customers.
Contact Us:
Polaris Market Research
Phone: 1-646-568-9980